EBay and Amgen: Dividends do Matter

William Smead
Chief Executive Officer
Chief Investment Officer

Dear Fellow Investors:

We are owners of both EBay (EBAY) and Amgen (AMGN). We believe the dividend policy and price action in the shares of these two companies can teach us about stock price performance over the next three to five years.

History shows that for a few decades after terrible stock price performance (like we’ve seen from 1999 to 2011) investors demand more of their return from cash dividends because they do not trust appreciation. In the 1940’s and early 1950’s, investors demanded a higher cash dividend from stocks than they demanded from Treasury and Corporate Bonds. Treasuries yielded around 2% in 1950 and the Dow had around a 6% yield from dividends. However, in the aftermath of the 1929-32 crushing bear market in stocks and massive bank failures which followed, public companies hoarded cash. Howard Silverblatt at S&P reports that the payout ratio in 1936 of US public companies was 29%. Ironically, in our opinion, we are in the same kind of circumstance and have the same kind of payout ratios today. See our June 1st, 2011 missive called “Cash Hoards” to understand the history more fully. Click here for missive.

Last summer, Amgen was trading in the low $50’s on a per share basis and had never paid a dividend as a public company. Amgen declared their first ever cash dividend at $.28 quarterly last summer. Since then, they did a Dutch auction, buying back 9% of their shares and raised the dividend to $.36 per quarter. Amgen’s first ever dividend was a higher yield on share price than the 10-year Treasury bond yield! I have been in the investment business for 31 years and can’t ever remember an initial dividend offering more than the 10-year Treasury interest rate. We believe it is no coincidence that Amgen is trading above $64 per share on December 29, 2011. At the $1.44 annualized dividend rate, it yields around 2.23%, still significantly above the Treasury bond yield.

Amgen still has a payout ratio below 30% and has massive free-cash flow. They could be an aggressive dividend growth company going forward as we believe their balance sheet is strong and the future earnings look bright. Their newest product Denosumab is selling briskly in the form of Prolia for Osteoporosis and Xgeva for treating cancerous tumors. Management seems to have learned what scared investors want from a company.

At the end of June in 2011, EBay closed at $32.27 per share. We believe they have a fortress balance sheet. Their PayPal division is growing like weeds and throwing off massive free-cash flow. Their legacy Marketplace business has turned the corner and is growing nicely, while continuing to throw off over a billion dollars in free cash flow. EBay is buying back stock, but they don’t pay a dividend. The stock was trading between $30 and $31 per share in the last week of 2011. Investors can’t help but like the operating results of EBay’s management team, but they are too scared from the last 12 years of non-existent price appreciation to bet on it alone.

Silverblatt pointed out that the historical payout ratio over the last 50 years is 52.6% and over the last 20 years it was 46%. At Smead Capital Management, we believe that the companies which raise their dividend payout ratio towards the historical averages from the position of strong balance sheets, wide moats and relatively non-cyclical earnings performance will enjoy the kind of outsized price gains that Amgen has seen in the second half of 2011. Hopefully, EBay will get the memo.

Best Wishes,

William Smead

The information contained in this missive represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results. Some of the securities identified and described in this missive are a sample of issuers being currently recommended for suitable clients as of the date of this missive and do not represent all of the securities purchased or recommended for our clients. It should not be assumed that investing in these securities was or will be profitable. A list of all recommendations made by Smead Capital Management with in the past twelve month period is available upon request.

We Advise Investors

Sign up to get our advice sent straight to your inbox.

Recent Missives

When Smart Money is Wrong

September 10, 2024

We learned a long time ago that we wanted to know what smart professional investors were doing. It’s always better to know who is smart rather than being smart yourself. Therefore, we’ve constantly...

⟶ Keep Reading

Same as it Ever Was

September 3, 2024

[...] Our large-cap value strategy is not the "same as it ever was," but it looks very attractive relative to the stock-picking disciplines we compete against. We own a portfolio that is cheaper...

⟶ Keep Reading

Markets Adapt to Your Style

August 27, 2024

[...] We believe the market has adapted to quality. Even the value players have adapted and most of them have attached quality to their marketing materials. The style has been adapted and we...

⟶ Keep Reading

Reuters: Bill Smead on Target and Other Retailers

August 21, 2024

  Target raises 2024 profit forecast after price cuts boost quarterly sales By Ananya Mariam Rajesh and Siddharth Cavale For more information go to reuters.com. Stocks mentioned: TGT The information […]

⟶ Keep Reading

Reuters: Cole Smead, CFA on Alimentation Couche-Tard

August 20, 2024

  Seven & i shares end lower on regulatory concerns over Couche-Tard bid By Ananya Mariam Rajesh and Juveria Tabassum For more information go to reuters.com. Stocks mentioned: ATD The […]

⟶ Keep Reading

Dear Chairman

August 13, 2024

As the investors of Smead Capital Management know, we focus on the shareholder friendliness of the businesses we analyze because we believe it can differentiate their long-term returns. Warren Buffett has said, “Own...

⟶ Keep Reading

We Advise Investors

Sign up to get our advice sent straight to your inbox.

US INVESTORS

Individual Investors

OR

Financial Advisors, Family Offices,
and Institutional Investors

OR

NON-US INVESTORS

Individual Investors

OR

Financial Advisors, Family Offices,
and Institutional Investors

OR

Scroll to Top